author-photo

Ryan Dittamore

Ventana Medical Systems

129

Papers

1847

Citations

Citation Trend

Filter By

Papers (76) Sort By

Journal Conference Others

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
INNV-36. NON-INTRUSIVE, NON-INVASIVE AND PATIENT FRIENDLY FOCUSED ULTRASOUND DEVICE AS A DELIVERY VEHICLE FOR CNS TUMORS

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Metastatic Genitourinary Cancer Patients.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Morphology-predicted large scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer.

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
MP55-09 ASSOCIATION OF AN IMMUNE-GENE SIGNATURE WITH PATHOLOGIC RESPONSE AND OUTCOME AFTER NEOADJUVANT PEMBROLIZUMAB (PEMBRO), COMPARED TO NEOADJUVANT CHEMOTHERAPY (NAC), IN MUSCLE-INVASIVE BLADDER CANCER (MIBC)

2020 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.

2020 European Urology Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer

2020
Show All
- Source
- Cite
- Save
Citations (1)
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer

2020 European Urology
Show All
- Source
- Cite
- Save
Citations (52)